The Trump administration advanced federal marijuana rescheduling in April 2026 by immediately placing FDA-approved cannabis products and state-licensed medical marijuana into Schedule III, while launching an expedited DEA administrative hearing on broader reclassification from Schedule I. That hearing ran from June 29 to July 15, 2026, with participants largely limited to rescheduling opponents; post-hearing briefs closed recently, and the DEA has argued in filings that marijuana meets Schedule III criteria due to accepted medical use and safety under supervision. A federal appeals court rejected challenges seeking to halt the process. The administrative law judge’s recommendation is pending, followed by a DEA Administrator decision and likely litigation, with Alabama recently withdrawing its objections. These steps shape trader views on timelines for any full rescheduling rule.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$812,403 Vol.
September 30
2%
December 31
22%
$812,403 Vol.
September 30
2%
December 31
22%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Pasar Dibuka: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The Trump administration advanced federal marijuana rescheduling in April 2026 by immediately placing FDA-approved cannabis products and state-licensed medical marijuana into Schedule III, while launching an expedited DEA administrative hearing on broader reclassification from Schedule I. That hearing ran from June 29 to July 15, 2026, with participants largely limited to rescheduling opponents; post-hearing briefs closed recently, and the DEA has argued in filings that marijuana meets Schedule III criteria due to accepted medical use and safety under supervision. A federal appeals court rejected challenges seeking to halt the process. The administrative law judge’s recommendation is pending, followed by a DEA Administrator decision and likely litigation, with Alabama recently withdrawing its objections. These steps shape trader views on timelines for any full rescheduling rule.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui



Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan